Interestingly, the first patient to enter the trial was found to be T0 at final pathology after radical prostatectomy despite a preoperative diagnosis of Gleason grade group 4 prostate cancer.21 Notably, this patient had a negative result on MRI yet had a positive grade for cancer on PSMA PET. This evidence concerns the gene FOLH1 and prostate carcinoma.